Q-omics provides the consensus-scored LRATD1 profile across patient tissues and cancer cell-line models. LRATD1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LRATD1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, LRATD1 RNA expression shows 17,972 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, THCA, and KIRP as cancer lineages where LRATD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRATD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRATD1 survival associations across molecular data types. LRATD1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRATD1 RNA expression–survival associations across cancer types. High LRATD1 expression shows unfavorable associations in UVM, KIRP, SKCM and LGG, but favorable associations in LUSC and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LRATD1 RNA expression.
This table summarizes LRATD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LRATD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRATD1 shows lower tumor expression in KICH and higher tumor expression in THCA, LUSC, UCEC, COAD and KIRP. The THCA box plot shows higher LRATD1 RNA expression in tumor versus normal tissue (log2 FC = +2.040, t-test p < 0.001).
This table shows molecular features associated with LRATD1 in patient tissues and cancer cell lines. In patient samples, LRATD1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, LRATD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_SCLC.
